|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
MPLW515K or W515L mutation plays an important role in the pathogenesis of myeloproliferative neoplasms (MPNs) through signaling molecules of the cytokine receptor axis.
|
31294534 |
2019 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations.
|
29042365 |
2017 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
|
25453399 |
2015 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.
|
24729973 |
2014 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Constitutively active JAK2V617F and thrombopoietin receptor (TpoR) W515L/K mutants are major determinants of human myeloproliferative neoplasms (MPNs).
|
19996410 |
2010 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Scanning of JAK2 exons 12-25 and MPL exon 10 revealed the presence of JAK2 alterations in six and MPL W515L/K mutations in five of 34 patients with myeloproliferative disorders.
|
19643476 |
2010 |
|
rs121913615
|
|
|
0.070 |
GeneticVariation |
BEFREE |
As JAK2 V617F, MPL W515L is a novel acquired mutation that induces constitutive cytokine-independent activation of the JAK-STAT pathway in myeloproliferative disorders (MPD).
|
18464114 |
2008 |
|
rs121913616
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The ability to simultaneously detect JAK2 V617F and MPL W515K/L mutations would substantially improve the early diagnosis of myeloproliferative neoplasms (MPNs) and decrease the risk of arterial thrombosis.
|
28819248 |
2017 |
|
rs121913616
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The thrombopoietin receptor gene (MPL) is expressed in megakaryocytes and exhibits the gain of function point mutation W515K/L in approximately 5% of patients with primary myelofibrosis/idiopathic myelofibrosis (PMF) representing one subtype of the chronic myeloproliferative disorders (myeloproliferative neoplasm).
|
19194467 |
2009 |
|
rs1476891431
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To analyze the relationship between six polymorphisms in genes related to oxidative stress, namely CAT-262 C>T, MnSOD Ala16Val, GPX1 Pro198Leu, GSTM1 and GSTT1 null genotypes, and GSTP1 Ile105Val, and the occurrence of BCR-ABL negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and primary myelofibrosis).
|
27077777 |
2016 |